This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Next revision Both sides next revision | ||
home:publications [16.11.2019 19:14] Teemu Kuulasmaa [2018] |
home:publications [09.12.2019 10:44] Teemu Kuulasmaa [2019] |
||
---|---|---|---|
Line 5: | Line 5: | ||
### 2019 | ### 2019 | ||
+ | |||
+ | Karttunen, J.; Heiskanen, M.; Lipponen, A.; Poulsen, D.; Pitkänen, A. **Extracellular Vesicles as Diagnostics and Therapeutics for Structural Epilepsies**, | ||
Failli M, Paananen J, Fortino V. **Prioritizing target-disease associations with novel safety and efficacy scoring methods**, //Sci Rep// 2019, https:// | Failli M, Paananen J, Fortino V. **Prioritizing target-disease associations with novel safety and efficacy scoring methods**, //Sci Rep// 2019, https:// | ||
- | Timonen O, Särkkä M, Fülöp T, Mattsson A, Kekäläinen J, Paananen J, **Varanto: variant enrichment analysis and annotation**, | + | Timonen O, Särkkä M, Fülöp T, Mattsson A, Kekäläinen J, Paananen J. **Varanto: variant enrichment analysis and annotation**, |
- | Lipponen A, Natunen T, Hujo M, Ciszek R, Hämäläinen E, Tohka J, Hiltunen M, Paananen J, Poulsen D, Kansanen E, Ndode-Ekane | + | Lipponen A, Natunen T, Hujo M, Ciszek R, Hämäläinen E, Tohka J, Hiltunen M, Paananen J, Poulsen D, Kansanen E, Ndode-Ekane |
- | Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman | + | Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman |
Mehtonen J, Pölönen P, Häyrynen S, Lin J, Liuksiala T, Granberg K, Lohi O, Hautamäki V, Nykter M, Heinäniemi M. **Data-driven characterization of molecular phenotypes across heterogenous sample collections**, | Mehtonen J, Pölönen P, Häyrynen S, Lin J, Liuksiala T, Granberg K, Lohi O, Hautamäki V, Nykter M, Heinäniemi M. **Data-driven characterization of molecular phenotypes across heterogenous sample collections**, | ||
//Nucleic Acids Research// 2019, https:// | //Nucleic Acids Research// 2019, https:// | ||
+ | |||
+ | Ngo Trong T, Mehtonen J, González G, Kramer R, Hautamäki V, Heinäniemi M. **Semisupervised Generative Autoencoder for Single-Cell Data.**, //J Comput Biol.// 2019, https:// | ||
+ | |||
+ | Nikkilä A, Arvela H, Mehtonen J, Raitanen J, Heinäniemi M, Lohi O, Auvinen A. **Predicting residential radon concentrations in Finland: Model development, | ||
+ | |||
+ | Sallinen H, Janhonen S, Pölönen P, Niskanen H, Liu OH, Kivelä A, Hartikainen JM, Anttila M, Heinäniemi M, Ylä-Herttuala S, Kaikkonen MU. **Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.**, | ||
+ | |||
+ | Pölönen P, Jawahar Deen A, Leinonen HM, Jyrkkänen HK, Kuosmanen S, Mononen M, Jain A, Tuomainen T, Pasonen-Seppänen S, Hartikainen JM, Mannermaa A, Nykter M, Tavi P, Johansen T, Heinäniemi M, Levonen AL. **Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma.**, | ||
+ | // | ||
+ | |||
+ | Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA. **Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.**, | ||
Line 41: | Line 54: | ||
### 2017 or earlier | ### 2017 or earlier | ||
- | - to be listed here later... | + | Paananen, J. **Bioinformatics in the Identification of Novel Targets and Pathways in Neurodegenerative Diseases**, Curr Genet Med Rep (2017) 5:15–21, https://doi.org/10.1007/ |